Latest Articlesddd
Before we sell PTC Therapeutics (PTCT), after the stock had reached and surpassed our latest and …
Portola (PTLA) has two important approved breakthrough products and an investigational product having promising results on …
When the Goal is Reaching into the Future, Pessimists Have No Place on the Ship The …
Celyad (CYAD) is an immuno-oncology firm, which created CAR T CELL treatments for cancers, including solid …
WE ARE LIVING AN HISTORIC BIOLOGICAL REVOLUTION. Unfortunately, the undeniably outstanding news has not yet penetrated …
Vertex Pharmaceuticals (VRTX) announced that the Pharmaceutical Benefits Advisory Committee’s (PBAC) in Australia recommendation the listing …
The FDA Approves Regeneron’s Product EyLea® (aflibercept) sBLA in Wet Age-Related Macular Degeneration Regeneron (REGN) has …
Aerie Pharmaceuticals (AERI) announced results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect …
The Week in Review #27 PRIORITY TOPICS: CRISPR GENE EDITING, GENETIC ENGINEERING & ANTISENSE TECHNOLOGY The choice of these …
Regeneron Pharmaceuticals (REGN) and bluebird bio, Inc. (BLUE) announced a collaboration to apply their respective technology platforms to the …
All the buying and selling of Portola (PTLA) will not make any sense to us until the …
When an investigational gene therapy gets excellent results, the usual reaction towards the developing firm is …
Exciting are the Q2 2018 reported results by Exelixis’ (EXEL) including the firm’s revenues and earnings, …
ProhostLetter #423 TOMORROW’S THERAPEUTICS TODAY For a more or less fair evaluation of biotechnology and pharmaceutical …
The Future is Starting Now Recognizing that the future has already started now is important as …
The Committee for Medicinal Products for Human Use (CHMP) announced a Positive Opinion recommending marketing authorization of Alnylam’s …
AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences (NBIX), announced that the United States FDA approved …
The good news from Biogen’s (BIIB) Q2 exciting financial results comprised impressive news for Ionis (IONS) …
Yesterday’s news unveiled that PTC Therapeutics (PTCT) has entered into an agreement to acquire Agilis Biotherapeutics. The …
Novartis’ (NVS) financials results exceeded analysts’ expectations. The firm’s research institutions’ strategy, well-designed structure, plans for …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
